DSIP Side Effects: What Trials, FDA and Reddit Users Report

DSIP side effects are less well mapped than most guides admit. The human safety record comes almost entirely from intravenous studies in the 1980s, and FDA's 2026 review found no safety data for the injection under the skin that people actually use. What exists points to a mild profile in most people, with a small number of low blood pressure events. What people report online is mostly vivid dreams, grogginess and nothing at all.

For the compound overview, see our DSIP peptide guide. The DSIP dosage chart covers doses and syringe math, and the DSIP benefits page covers what it may do. This page stays on harms.

DSIP side effects documented in human studies

The best numbers come from a 1984 French study of alcohol and opiate withdrawal. Researchers gave DSIP intravenously to 107 inpatients and assessed the response clinically (Dick 1984, PMID 6548969). The original abstract says tolerance was good, apart from headaches in a few patients. FDA's 2026 briefing document went back through the paper and counted the events more closely, which gives the chart below.

Of the three serious events, two were low blood pressure at the start of the first injection. The third patient had repeated episodes of general discomfort with sweating and nausea lasting 15 minutes. FDA also notes one patient who received a second injection and developed what the paper called "progressive hypotension." The agency adds a caveat that matters: withdrawal itself causes sweating, nausea and anxiety, so it is hard to say which symptoms came from DSIP. The author also attributed some reactions to solubility problems with some of the vials, which is a reminder that product quality can look like a side effect.

The other human data are smaller. In the first human study, six healthy volunteers received 25 nmol/kg intravenously and the authors reported it was well tolerated with no psychological, physiological or biochemical side effects (Schneider-Helmert 1981, PMID 6895513). FDA's summary adds that five of the six felt a "pressure to sleep" right after the infusion. In a six-person crossover in people with chronic insomnia, FDA reports a slight arousing effect in the first hour after the injection, with sleep-promoting effects starting in the second hour. That is the opposite of what many people expect, and it is one reason timing and infusion speed come up so often. The 1983 multi-study report called slow injection essential (PMID 6689058).

In total FDA counted 209 people given 25 to 150 nmol/kg intravenously for 1 to 15 days. The controlled insomnia trials reported no significant adverse effects, though they were small and short (Bes 1992, PMID 1299794). One more detail from the withdrawal study: some patients treated for opioid withdrawal relapsed into anxiety with marked insomnia 24 to 72 hours after treatment stopped. That reflects the underlying condition, not DSIP dependence, but nobody has studied what happens when a healthy person stops.

What nobody has measured

FDA's review is blunt about the gaps, and they cover almost everything a home user cares about.

• Subcutaneous and nasal use. No clinical safety data for the nominated subcutaneous injection, and no pharmacokinetic or toxicology studies by that route.
• Repeated dosing. FDA found no repeat-dose toxicity studies, and the human data stop at 15 days.
• Pregnancy and breastfeeding. FDA found no developmental or reproductive toxicity studies. "No data" means unknown, not safe.
• Drug interactions. No formal interaction studies were identified in the briefing document.
• Animal safety signals. The one acute study FDA cites gave rats a single 0.1 mg/kg injection: blood pressure was unchanged, heart rate fell about 3 percent in the day and about 10 percent in the evening, and the daily temperature rhythm shifted. Whether that matters for people is unknown.

FDA also flagged a concern that applies to any injected peptide: aggregation and impurities can trigger an immune response, and injection under the skin is generally more immunogenic than intravenous dosing. It noted that endotoxin and impurity testing for DSIP was missing from the literature it reviewed. FDA proposed not adding DSIP to the 503A compounding list, and news coverage says the advisory committee also voted against it, 6 to 7 (I could not confirm that vote on FDA's site). The practical point is that "side effects" of a research vial include whatever else is in it.

The card below summarizes the human safety numbers behind this section.

What Reddit users report

I read 444 scraped Reddit items from 12 subreddits and 24 threads (r/NTNPerformance supplied 291, r/Biohackers 77 and r/BodyHackGuide 66). Most were guide posts, vendor posts, comments about other peptides, and a 77-item thread about FDA policy. After removing those, 9 comments or posts in 6 threads from just 2 subreddits (r/BodyHackGuide and r/NTNPerformance) described first-hand DSIP use. That is far too few for a pattern, and the sample is self-selected: people who had a bad time may simply not post.

Of the 9: five were positive about sleep and mentioned no problem, one was positive and said there was no morning grogginess, one used a nasal blend of DSIP, melatonin and GABA and felt a slight burn going in, one said it did nothing, and one had a bad time.

The bad one: a poster who tried DSIP and NAD+ together within a stack of other compounds wrote "DSIP & NAD+: These gave me terrible nightmares, so I only took them for two days in a row." They also felt lethargic and sleepy for the whole day (a r/BodyHackGuide poster, Jun 2026). Two compounds at once means the cause is unclear. On the other side, a commenter wrote "DSIP is absolutely helping Deep and REM. I don't notice morning groggy." (a r/NTNPerformance commenter, Sep 2026)

The guide-style posts in the file say more than the first-hand reports do. Six of them list side effects, and they draw from the same template: morning grogginess at higher doses, vivid dreams, mild headache, occasional nausea, injection-site irritation, and rarely low blood pressure. One calls morning grogginess the most common DSIP complaint, but gives no count. Treat that as a plausible pattern, not a measured one.

Claims to read carefully. A vendor-run post lists serious adverse effects as none documented at research doses. The record FDA summarized does include three serious events in 107 patients, two of them hypotension. Another guide states that the compound is easily tolerated because it occurs naturally in the body. The peptide being endogenous says nothing about the safety of a synthetic injectable at several times natural levels. Another claim, that DSIP is a gentle alternative to prescription sleep drugs without dependency concerns, is marketing, not evidence.

How people manage side effects, and when to stop

The management advice in Reddit guides is simple: take less, or take it earlier in the evening, if you feel groggy. One NTNPerformance guide adds that the effect depends on circadian timing and that DSIP should not be run with Z-drugs, benzodiazepines or alcohol, because the mechanisms overlap. The mechanism claim is unproven. The caution itself is sensible, since no one has tested DSIP alongside sedatives and the two could stack.

My own approach is more conservative. A side effect from an unapproved injectable, in an unregulated product, is a reason to stop and talk to someone qualified, not to experiment with a lower dose. Use the grid below as a minimum, and tell the clinician what you injected, from where, and how much.

Product quality is part of safety

Research vials are not made or checked to pharmaceutical standards, and FDA's concerns about impurities and endotoxin apply to them directly. Ascension Peptides lists DSIP 10 mg at $60.00 as of 2026-10-11 (list price $94.99), and says Kovera Labs tests every batch for HPLC purity, LC-MS identity, net content, endotoxin, sterility and heavy metals, with over 98% of batches passing and public batch COAs. Prices are in USD, shipping is US only and all sales are final. A first-time buyer can use code PEPTIDEDECK for 50% off. Testing addresses the contamination and mislabeling risk FDA raised; it does not make DSIP approved or its safety proven.

Interactions and who should avoid DSIP

No formal interaction data exist, so this list comes from inference and from the gaps above.

• Sedatives and sleep medications (benzodiazepines, Z-drugs, sedating antihistamines, alcohol). Untested in combination. Overlapping sedation is the risk.
• Opioids and withdrawal. Early work proposed that DSIP acts on opioid pathways, and the withdrawal study was clinic-supervised IV treatment. Self-treating withdrawal is not something the evidence supports.
• Blood pressure drugs and low blood pressure. Because hypotension appeared in the human record, someone already prone to fainting or on antihypertensives has more reason to be cautious. That is an inference, not a studied interaction.
• Pregnancy, breastfeeding, children. No reproductive or pediatric data.
• Untreated sleep apnea or unexplained insomnia. DSIP is not a diagnosis. A clinician can screen for apnea and offer tested treatments, including CBT for insomnia.

Frequently Asked Questions

What are the side effects of DSIP?

In human trials, mostly mild: headache, sweating, nausea and vertigo in a minority, with a few cases of low blood pressure after intravenous injection. Online users mention vivid dreams and morning grogginess. Long-term and subcutaneous safety are unstudied.

Is DSIP safe?

It has not been shown to be safe or unsafe for home use. The human studies were small, intravenous and short. FDA called the safety information insufficient in its 2026 review and recommended against adding it to the compounding list.

Does DSIP cause grogginess the next day?

Many guides say so at higher doses, and one Reddit commenter reported daytime sleepiness. The first-hand Reddit sample is too small to say how common it is. A reasonable reading is that next-day heaviness is possible and dose may matter.

Can you take DSIP with melatonin, alcohol or sleep medication?

No study has tested it. Alcohol and prescription sedatives add their own sedation, and combining them with an unstudied peptide makes any bad reaction impossible to attribute. Ask a clinician before mixing.

Does DSIP cause dependence or withdrawal?

Guides often say it does not. I found no human study that tested stopping DSIP in healthy people. The withdrawal-treatment study found rebound anxiety and insomnia after treatment ended in some opioid patients, but that reflects the condition being treated.

Where to buy research-grade DSIP

If you decide to buy research material despite the unknowns above, Ascension Peptides lists DSIP 10 mg at $60.00 as of 2026-10-11, with Kovera Labs batch testing and public COAs. Read the warning signs in this article first, and speak with a clinician if you have a health condition or take medication. Our guide to buying DSIP compares vendors.